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ABSTRACT:
Microvascular proliferation is a key biological and diagnostic hallmark of human 
glioblastoma, one of the most aggressive forms of human cancer. It has recently 
been suggested that stem-like glioblastoma cells have the capacity to differentiate 
into functional endothelial cells, and that a significant proportion of the vascular lining 
in tumors has a neoplastic origin. In principle, this finding could significantly impact 
the efficacy and development of antiangiogenic therapies targeting the vasculature. 
While the potential of stem-like cancer cells to form endothelium in culture seems 
clear, in our clinical experience using a variety of molecular markers, neoplastic 
cells do not contribute significantly to the endothelial-lined vasculature of primary 
human glioblastoma. We sought to confirm this impression by analyzing vessels in 
glioblastoma previously examined using chromogenic in situ hybridization (CISH) for 
EGFR and immunohistochemistry for mutant IDH1. Vessels containing cells expressing 
these definitive neoplastic markers were identified in a small fraction of tumors, 
but only 10% of vessel profiles examined contained such cells and when identified 
these cells comprised less than 10% of the vascular cellularity in the cross section. 
Interestingly, these rare intravascular cells showing EGFR amplification by CISH or 
mutant IDH1 protein by immunohistochemistry were located in the middle or outer 
portions of vessel walls, but not amongst the morphologic boundaries of the endothelial 
lining. To more directly address the capacity of glioblastoma cells to contribute to the 
vascular endothelium, we performed double labeling (Immunofluorescence/FISH) 
for the endothelial marker CD34 and EGFR gene locus. Although rare CD34 positive 
neoplastic cells unassociated with vessels were identified (<1%), this analysis did 
not identify EGFR amplified cells within vascular linings, and further supports our 
observations that incorporation of glioblastoma cells into the tumor vessels is at best 
extremely rare, and therefore of questionable clinical or therapeutic significance.
INTRODUCTION
Glioblastoma represents the most common primary 
malignant brain tumor in humans [1], with an incidence 
of 3.19 per 100,000 person years in the United States[2]. 
These are highly aggressive neoplasms, with very poor 
overall survival despite combined chemotherapeutic 
and radiotherapy regimens [3]. Recent large scale 
genomic  studies  have  clarified  the  common  somatic 
genetic alterations that occur in human glioblastoma. 
Many target well known cellular signaling pathways, 
including receptor tyrosine kinase/RAS/PI3K, p53 and 
RB [1, 4]. Specific molecular alterations affecting these 
pathways include amplifications and mutations in EGFR 
and PDGFR, as well as mutations or deletions in tumor 
suppressor genes including PTEN,  CDKN2A,  TP53, Oncotarget 2012; 3:  98 - 106 99 www.impactjournals.com/oncotarget
RB1, and NF1 [5-9]. Many of these alterations affect 
key biological properties of glioblastoma, including 
proliferation and cell invasion[10]. More recently, point 
mutations affecting metabolic proteins such as IDH1 
or IDH2 have been found in the majority of infiltrating 
gliomas and a subset of glioblastomas [11-13]. The most 
frequent IDH1 mutant protein (R132H) can be identified 
by a specific antibody using immunohistochemistry [14, 
15], facilitating precise localization of tumor cells.
It has also become clear that glioblastomas are quite 
heterogeneous, with stem-like cells, better differentiated 
components, and stromal cells all playing key roles in the 
growth of a neoplasm [16]. Until recently, it was thought 
that blood vessels and other stromal elements were 
recruited into the growing tumor from non-neoplastic 
sources. Several provocative recent studies, however, 
have suggested that stem-like glioblastoma cells (cancer 
stem cells) are able to differentiate into functional vascular 
endothelium, and contribute significantly to the blood 
vessels supporting tumor growth [17-19]. If true, this 
would have major implications in terms of how tumor 
vessels are targeted therapeutically. However, based on 
our routine clinical practice as surgical neuropathologists 
vessels rarely seemed to contain mutant tumor cells 
and therefore we sought to perform a more formal and 
quantitative analysis of genetic changes in glioma vessels. 
We find that the contribution of neoplastic cells to tumor 
endothelium is small at best, and below routine detection 
in many tumors. Below, we review literature on the topic 
of angiogenesis in glioma, and present data which supports 
our perspective on the issue of neoplastic contribution to 
glioblastoma vasculature.
Angiogenesis  is  a  defining  property  of  human 
glioblastoma
One of the most important morphologic features 
of glioblastoma is the presence of microvascular 
proliferation [20]. Indeed, such “glomeruloid” vessels 
are part of the histologic diagnostic criteria in the current 
WHO  classification  scheme  [20].  Florid  angiogenesis 
in glioblastoma often represents a response to hypoxia 
in the neoplastic microenvironment, and is frequently 
found surrounding areas of pseudopalisading necrosis 
[21]. Hypoxia leads to an increase in angiogenic 
factors, including VEGF [22] resulting in microvascular 
hyperplasia and endothelial sprouting from pre-existing 
vessels [21, 23]. In addition, recent studies support the 
induction of angiogenesis by human glioma stem cells 
[24], mediated in part by hypoxia [25-27], and suggest that 
perivascular stem cell niches can play an important role in 
brain tumor pathobiology [28-32]. There is an evolving 
literature of interactions/cross talk between glioma cells 
and endothelium, which involves important pathways such 
as the Ang1/Tie2 signaling axis[33, 34].
The importance of adequate vasculature and blood 
flow in glioblastoma and other tumors has resulted in the 
development of a number of novel therapies and laboratory 
approaches that target angiogenesis[35-37]. This is 
conceptually simpler than targeting tumor cells, as the 
microvasculature was long thought to be non-neoplastic 
and to lack genetic instability often associated with 
treatment resistance [38]. In the field of neurooncology, 
bevacizumab, a humanized monoclonal antibody against 
VEGF-A, represents an approved treatment strategy for 
recurrent glioblastoma [39-41]. 
Vasculogenic mimicry
In addition to conventional angiogenic mechanisms, 
alternative ways to increase vascular delivery to human 
tumors have been proposed, including incorporation of 
endothelial precursors from bone marrow [42-44] and 
“vasculogenic mimicry” by tumor cells. The phenomenon 
of vasculogenic mimicry, whereby neoplastic cells create 
channels  lacking  endothelium  that  conduct  fluid  [45], 
has been explored in a variety of cancer types, including 
melanoma, carcinomas, sarcomas, and even glioblastoma 
[46-51]. Several investigators have described the presence 
of neoplastic, non-endothelial lining in such structures by 
a variety of morphologic and molecular methods [52-54].
In glioblastoma the phenomenon of vasculogenic 
mimicry was recently studied by El Hallani et al., who 
described the formation of vascular-like channels in tissue 
sections from human glioblastoma [47]. They differed 
from true vessels by lack of CD34 expression in luminal 
cells demonstrating EGFR amplification by Fluorescence 
In  Situ  Hybridization  (FISH), supporting the concept 
that these cells are not endothelial. Follow-up in vitro 
studies using CD133+ stem-like cells cultures from 
glioblastomas demonstrating channel formation, resulted 
in tubular structures in 3D matrigel, and expression of 
genes associated with vasculogenic mimicry (e.g. EphA2, 
laminin, neuropilin-2), but a consistent lack of endothelial 
marker expression. Interesting as these results may be, 
the extent of the potential contribution of vasculogenic 
mimicry to blood flow to glioblastoma in unclear at the 
present time.
Neoplastic  contribution  to  endothelial-lined 
microvasculature in glioblastoma?
Studies from several investigators have raised 
the possibility that true endothelial linings may have 
a neoplastic origin in some human cancers, including 
lymphoma and neuroblastoma [55, 56], and contain 
cytogenetic aberrations in cultures from primary tumors 
and in xenograft model systems [57, 58]. The capacity of 
tumor-derived stem cells to differentiate into endothelium 
and participate in the formation of microvasculature has 
also been studied recently in breast cancer [59]. Finally, it Oncotarget 2012; 3:  98 - 106 100 www.impactjournals.com/oncotarget
has been suggested that non-neoplastic neural stem cells 
can differentiate into endothelial cells in vitro [60].
 In recent elegant studies using in vitro systems, 
transgenic models and primary human tumors [17-
19], the hypothesis that neoplastic cells in glioblastoma 
contribute to the microvasculature by differentiating into 
endothelial cells was further explored. These groups 
described the differentiation of stem-like glioblastoma 
cells into endothelium in vitro, and their incorporation 
into tumor-associated blood vessels in vivo. This 
represents an interesting extension of the cancer stem cell 
hypothesis, and opens the possibility that a small fraction 
of multipotent cells may give rise not only to the main 
tumor mass [61, 62], but also its microvasculature. 
In one of these studies, Ricci-Vitiani et al. found 
CD31 positive endothelial cells to label with p53 protein, 
and  in  double  immunofluorescence/FISH  experiments 
reported alterations in chromosomes 10, 19q, and 22q 
in neoplastic cells and a subset of endothelial cells. 
Follow-up  quantification  experiments  using  freshly 
dissociated  glioblastomas  demonstrated  tumor-specific 
cytogenetic aberrations in between 20-90% of sorted 
putative endothelial cells. Cultured glioblastoma stem-
like cells differentiated into endothelial cells in vitro and 
produced tumors in xenografts containing human-derived 
endothelial cells. Using similar approaches, Wang et al. 
demonstrated  EGFR/Chromosome 7 abnormalities in 
CD105+ putative endothelial cells obtained from human 
glioblastomas, as well as endothelial differentiation from 
CD133+ tumor stem-like cells, thought to occur through 
a CD133+/CD144+ endothelial progenitor. Importantly, 
this second group also felt that neoplastic cells 
contributed significantly to the glioblastoma vasculature 
in human specimens, and stated that the proportion of 
CD105+ endothelial cells with extra copies of EGFR or 
chromosome 7 was comparable to the proportion of tumor 
cells with the same aberrations. 
A subsequent study by Soda et al. predominantly 
used  a  murine  glioblastoma  model  expressing  GFP, 
H-ras, and Akt, coupled with p53 loss, in GFAP+ cells 
[19]. In these animals a subset of tumor vasculature co-
expressed  GFP  and  endothelial  markers.  Additional 
functional experiments suggested that the endothelial 
differentiation was induced by hypoxia, and resistant to 
anti-VEGF therapy. Collectively, these studies suggest 
a  new  paradigm  in  the  field  of  angiogenesis:  namely 
that genetically altered tumor cells help form their 
own microvasculature. These concepts have important 
scientific  therapeutic  implications,  highlighted  by  the 
preliminary investigations of the effects of anti-VEGF 
therapy on neoplastic endothelium in two of the above 
studies [17, 19]. 
Lack of endothelial neoplastic molecular changes 
in clinical glioblastoma specimens
While even a limited cancer stem cell contribution 
to the vasculature of glioblastoma would be of basic 
biological interest, for such a process to be of functional 
significance in therapeutic planning the tumor-derived 
cells would need to comprise a sizable fraction of the 
vascular endothelium. As clinical neuropathologists, we 
routinely examine glioblastoma and other brain tumors 
with prominent neovascularization using a variety of 
markers. In our experience, tissue based techniques such 
as  FISH,  Chromogenic  In  Situ  Hybridization  (CISH) 
and immunohistochemistry consistently show molecular 
abnormalities to be limited to non-vascular tumor cells. 
This clinical experience suggests that while stem-like 
glioblastoma cells may have the capacity to differentiate 
into endothelium, they are unlikely to play a major role in 
forming the pathological vasculature in patients with brain 
tumors as suggested in recent reports.
Markers we have examined in glioblastomas include 
EGFR, PDGFRA, and PTEN copy number alterations 
using FISH or CISH, as well as alterations in IDH1, 
EGFR, p53 or PTEN protein using immunohistochemistry. 
Significantly, in our routine clinical work we have not 
encountered tumors in which neoplastic molecular changes 
were common in cells within the morphologically-defined 
vascular components of glioblastoma. Indeed, the tumor 
vasculature is routinely used as an internal negative 
control in such studies. Examples of normal staining in 
glioblastoma vessels are shown in Figure 1, including 
intact PDGFRA copy number in vessels with surrounding 
tumor demonstrating amplification of the receptor (Figure 
1a), and overexpression of EGFR or loss of PTEN protein 
in glioblastoma cells with vascular structures failing to 
show such changes (Figure 1b,c). Such experience, while 
“anecdotal”, includes the examination of thousands of 
tumors by the authors, all of whom are board-certified 
neuropathologists. 
To augment our clinical impressions, we have 
recently reviewed a number of cases using several 
techniques.  First,  we  examined  24  malignant  gliomas 
which showed strong immunoreactivity for mutant IDH1, 
including 9 GBM, 13 anaplastic astrocytomas, and 2 
anaplastic oligodendrogliomas identified on two glioma 
tissue microarrays generated at Johns Hopkins Hospital. 
The three to four cores per tumor on the microarrays 
included  between  4  and  51  vessel  profiles  (mean  18 
vessel  profiles  per  tumor),  all  of  which  were  closely 
examined for mutant IDH1 protein similar to that seen 
in the surrounding infiltrating tumor cells. Most vessels 
showed no immunoreactivity for mutant IDH1 (Figure 
1d). As illustrated in Figure 1e, glial-appearing IDH1-
immunoreactive cells were found surrounding vascular 
structures in many tumors, consistent with the known 
predilection  of  infiltrating  gliomas  to  satellite  around Oncotarget 2012; 3:  98 - 106 101 www.impactjournals.com/oncotarget
blood vessels [20]. However, cells expressing this 
neoplastic marker were only found within the vessel wall 
in 1 of the 24 cases (4%). The case contained two vessels 
with single IDH1-positive cells within the vascular wall 
(Figure 1f). Importantly, in none of the tumors did we 
identify IDH1 positive cells definitively lining the vascular 
lumen, and all such endothelial cells were non-neoplastic 
based on this marker.
We also re-reviewed 10 glioblastoma cases from 
Brigham and Women’s Hospital with high level EGFR 
amplification based on clinical CISH analysis. Ten random 
vascular profiles were scored in each tumor, most of which 
represented microvascular proliferations, although some 
normal-appearing vessels were analyzed as well. In 6 
of the tumors examined, no EGFR-amplified cells were 
present within or attached to blood vessels (Figure 1g). 
In 3 glioblastomas, rare EGFR-amplified cells (1 cell in 
1/10 vessels) were identified attached to the outer aspect 
of tumor vasculature but not definitively within the wall 
(Figure 1h). Finally, in one tumor, a few neoplastic cells 
were identified within the vessel wall (Figure 1i). In these 
latter 4 cases with EGFR-amplified cells in or around 
blood vessels, the percentage of vascular or perivascular 
neoplastic cells was always less than 10% of the overall 
blood vessel cellularity. Also, as with IDH1 staining, no 
cells lining the vessels showed increased EGFR copy 
number using CISH, supporting the concept that the 
endothelial lining was not derived from the surrounding 
tumor. 
To more directly address the contribution of 
neoplastic cells to vascular endothelium, we concurrently 
examined EGFR gain and endothelial marker expression 
Figure 1: Glioma specific molecular alterations are not a common feature of endothelial tumor vasculature in clinical 
samples. (a) PDGFRA amplification in tumor cells (arrow) but not in endothelial cells (arrowheads) in adjacent vessel (V).  (b and c) 
Molecular alterations in neoplastic cells by immunohistochemistry, but not in vasculature (V), including EGFR overexpression (b) and 
PTEN loss (c).  Quantification of vessels in tumors stained for IDH1 R132H mutant protein by immunohistochemistry (d-f) or EGFR 
amplification by CISH (g-i) revealed that most tumor cells showed positive staining, whereas the vessels (V) were devoid of signal (d and 
g).  Tumor cells were found to crowd the perivascular region (e and h), but only rare vessels contained positive cells within the vascular 
wall (f and i).Oncotarget 2012; 3:  98 - 106 102 www.impactjournals.com/oncotarget
in a cohort of 86 glioblastomas on the Johns Hopkins 
tissue microarrays. These combined immunofluorescence/
FISH studies were performed using an anti-CD34 antibody 
with a FITC labeled secondary antibody, and FISH probes 
targeting EGFR/centromere 7. Only CD34+ endothelial 
cells (i.e. present in the lining of a vascular lumen) 
were studied. All fields were scanned for vessels that 
demonstrated clear CD34 immunoreactivity and EGFR 
co-hybridization. Cytogenetic abnormalities in tumors 
were scored using previously published cutoffs [63].
Among the 86 tumors, 32 (37%) showed EGFR 
amplification,  and  an  additional  35  (41%)  gain  of 
chromosome 7. A total of 4974 CD34+ cells in 971 
vessels were examined in the 86 glioblastomas, including 
3852 CD34+ cells in 768 vessels from tumors showing 
EGFR amplification or gain of chromosome 7. No EGFR 
amplified/CD34+  endothelial  cells  were  identified  in 
any case. The majority of the CD34+ endothelial cells 
contained 1-2 EGFR copies (Figure 2a), with only 27 
cells (0.005%) containing 3-4 copies. The number of 
CD34+ endothelial cells with extra EGFR copies was 
similar in glioblastomas with chromosome 7 gain or 
EGFR amplification and the smaller subset lacking such 
abnormalities (p=0.8, Fisher Exact Test). This suggests 
that random nuclear overlap may explain the low-level 
extra EGFR copy numbers we observe in rare cells. 
DISCUSSION
The plasticity of glioblastoma has long been 
recognized, and until recently this tumor was known as 
“glioblastoma multiforme” in recognition of its varied 
cellular composition. Divergent differentiation in the form 
of mesenchymal elements, including neoplastic bone[64], 
cartilage [65], skeletal muscle [66], smooth muscle [67], 
and adipose tissue [68], as well as epithelial structures [63] 
have all been described in glioblastoma, particularly the 
subtype known as “gliosarcoma”. It is also increasingly 
clear that glioblastoma and other malignancies contain 
stem-like cells which can be maintained in serum-free 
media as spheres and have the potential to differentiate 
along a number of lineages. We therefore do not doubt one 
central finding of recent elegant studies by several groups 
- that malignant glioma cells have the capacity to express 
endothelial markers and incorporate into blood vessels 
[17-19]. 
However, as practicing neuropathologists who 
routinely assess a variety of molecular markers in primary 
human tumors, we do question the degree to which this 
phenomenon actually occurs in patients. Our data suggest 
that very few vascular cells in human glioblastoma harbor 
the molecular changes which define the surrounding tumor. 
These results are consistent with a prior microdissection-
based study, in which glomeruloid p53 immunoreactive 
endothelial cells in glioblastoma lacked tumor-specific 
mutations [69]. 
A number of potential caveats apply to the study 
of neoplastic endothelium. First, it is possible that small 
groups of tumor cells which do not form morphologically-
recognizable vessels may express endothelial markers, 
and that such cells contributed to those isolated by 
Wang et al. [17] and Ricci-Vitiani et al. [18] using flow 
Figure 2: Lack of significant EGFR alterations in CD34 positive endothelial cells. EGFR amplifications in glioblastoma 
neoplastic cells (arrowheads), but lacking in associated CD34+ endothelial cells (arrows)(a). Orange autofluorescence frequently identified 
intraluminal red blood cells (asterisks). Only a minority of CD34+ cells demonstrated extra EGFR copies, and at a similar frequency in 
glioblastomas with and without chromosome 7/EGFR abnormalities (b). Oncotarget 2012; 3:  98 - 106 103 www.impactjournals.com/oncotarget
cytometric approaches lacking spatial cues. In addition, 
because of the intimate relationship between glial tumor 
processes and adjacent blood vessels, it can sometimes 
be  difficult  to  unambiguously  distinguish  glial  tumor 
cells from vasculature particularly as obtaining single 
cell suspensions is challenging in brain tumors. Another 
consideration would be that GBM cells are able to 
transmigrate across the vessel wall in order to enter into 
the bloodstream and might therefore be observed during 
their migration. Finally, genetic heterogeneity exists in 
glioblastoma, including mosaic amplification of receptors 
such as EGFR [70], potentially complicating distinctions 
between neoplastic and non-neoplastic cells.
 It is possible that small numbers of neoplastic cells 
contribute to the endothelium of glioblastoma. Indeed, as 
shown in Figure 1, rare cells within the vessel walls can 
express molecular markers of neoplastic transformation. 
However, in neither our large anecdotal clinical experience 
nor the more focused analysis described above have we 
observed a significant contribution by neoplastic cells to 
the tumor microvasculature as suggested in recent reports. 
Specifically,  we  feel  that  most  glioblastoma  vessels 
contain no neoplastic cells, and when they are present 
they comprise less that 10% of the vessel cellularity. It 
also appears to us that the rare neoplastic cells within 
tumor vessels do not incorporate into the endothelial 
vascular lining or express the endothelial marker CD34. 
We therefore believe that while recent demonstrations of 
cancer stem cell plasticity are of significant basic research 
interest, the clinical and in vivo biological relevance of 
the capacity of stem-like glioblastoma cells to give rise to 
endothelium remains unclear, and current efforts to exploit 
the genotypic/phenotypic differences between tumors and 
their associated vasculature should not be abandoned. 
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